• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study.

作者信息

Yanai Henit, Dotan Iris

机构信息

IBD Center, Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel.

出版信息

J Crohns Colitis. 2019 Apr 26;13(5):539-540. doi: 10.1093/ecco-jcc/jjy202.

DOI:10.1093/ecco-jcc/jjy202
PMID:30535008
Abstract
摘要

相似文献

1
Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study.治疗药物监测在炎症性肠病中英夫利昔单抗反应丧失的管理中比基于临床的方法更具成本效益：一项观察性多中心研究。
J Crohns Colitis. 2019 Apr 26;13(5):539-540. doi: 10.1093/ecco-jcc/jjy202.
2
Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study.治疗药物监测在炎症性肠病中对抗肿瘤坏死因子治疗应答丧失的管理中比基于临床的方法更具成本效益：一项观察性多中心研究。
J Crohns Colitis. 2018 Aug 29;12(9):1079-1088. doi: 10.1093/ecco-jcc/jjy076.
3
Therapeutic drug monitoring is predictive of loss of response after de-escalation of infliximab therapy in patients with inflammatory bowel disease in clinical remission.治疗药物监测可预测临床缓解的炎症性肠病患者英夫利昔单抗治疗降阶梯后反应丧失的情况。
Clin Res Hepatol Gastroenterol. 2016 Feb;40(1):90-8. doi: 10.1016/j.clinre.2015.05.019. Epub 2015 Jun 29.
4
Editorial: infliximab de-escalation in inflammatory bowel disease using a therapeutic drug monitoring strategy-early promise but more data needed.
Aliment Pharmacol Ther. 2019 Mar;49(6):816-817. doi: 10.1111/apt.15081.
5
Primary and secondary nonresponse to infliximab: mechanisms and countermeasures.英夫利昔单抗的原发性和继发性无应答：机制与对策
Expert Opin Drug Metab Toxicol. 2017 Oct;13(10):1039-1046. doi: 10.1080/17425255.2017.1377180. Epub 2017 Sep 11.
6
Clinical value and cost saving of therapeutic drug monitoring of infliximab in adult patients with inflammatory bowel disease.英夫利昔单抗治疗药物监测在成年炎症性肠病患者中的临床价值及成本节约情况
Clin Med (Lond). 2020 Mar;20(Suppl 2):s23-s24. doi: 10.7861/clinmed.20-2-s23.
7
Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease.综述文章：炎症性肠病中英夫利昔单抗治疗药物监测的临床医生指南。
Aliment Pharmacol Ther. 2013 Sep;38(5):447-59. doi: 10.1111/apt.12407. Epub 2013 Jul 14.
8
Therapeutic Drug Monitoring to Guide Infliximab Dose Adjustment is Associated with Better Endoscopic Outcomes than Clinical Decision Making Alone in Active Inflammatory Bowel Disease.在活动性炎症性肠病中，与仅依靠临床决策相比，通过治疗药物监测来指导英夫利昔单抗剂量调整与更好的内镜检查结果相关。
Inflamm Bowel Dis. 2017 Jul;23(7):1202-1209. doi: 10.1097/MIB.0000000000001126.
9
Reactive Versus Proactive Therapeutic Drug Monitoring in Inflammatory Bowel Disease Patients Treated With Infliximab: A Self-Fulfilling Prophecy.接受英夫利昔单抗治疗的炎症性肠病患者中反应性与前瞻性治疗药物监测：自我实现的预言
Clin Gastroenterol Hepatol. 2017 Oct;15(10):1638. doi: 10.1016/j.cgh.2017.05.017. Epub 2017 May 18.
10
Letter: therapeutic drug monitoring and inflammatory bowel disease-a call for an urgent standardization of the results.
Aliment Pharmacol Ther. 2018 Feb;47(3):448-449. doi: 10.1111/apt.14456.

引用本文的文献

1
The role of proactive therapeutic drug monitoring in guiding infliximab therapeutic optimization in pediatric patients with Crohn's disease: A retrospective study.前瞻性治疗药物监测在指导克罗恩病患儿英夫利昔单抗治疗优化中的作用：一项回顾性研究。
Pediatr Discov. 2024 Jun 25;2(4):e96. doi: 10.1002/pdi3.96. eCollection 2024 Dec.
2
Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review.炎症性肠病中抗TNF治疗药物监测的成本效益：一项系统评价
Pharmaceutics. 2022 May 7;14(5):1009. doi: 10.3390/pharmaceutics14051009.
3
Surface plasmon resonance unveils important pitfalls of enzyme-linked immunoassay for the detection of anti-infliximab antibodies in patients' sera.
表面等离子体共振揭示了酶联免疫吸附试验检测患者血清中抗英夫利昔单抗抗体的重要陷阱。
Sci Rep. 2021 Jul 22;11(1):14976. doi: 10.1038/s41598-021-94431-x.